Portland, OR
Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical developme... Read more
sparrowpharma.comThese are collections Sparrow Pharmaceuticals is a part of. Click on the collection name to view similar companies.
Series B
$95,000,000
Series Unknown
$10,200,000
Series A
$50,000,000
Series Unknown
$1,075,255
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Sparrow Pharmaceuticals.